Navigation Links
Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced
Date:4/17/2008

Phase II data from study of GAMMAGARD-treated patients announced at the

American Academy of Neurology annual meeting

CHICAGO, April 17 /PRNewswire-FirstCall/ -- New York-Presbyterian Hospital/Weill Cornell Medical Center and Baxter International Inc. (NYSE: BAX) announced results of a six-month, placebo-controlled Phase II study of 24 patients treated with GAMMAGARD S/D and GAMMAGARD LIQUID [Immune Globulin Intravenous (IGIV)] for the treatment of mild-to-moderate Alzheimer's disease today at the American Academy of Neurology (AAN) annual meeting in Chicago. The study met the primary endpoint criteria favoring GAMMAGARD LIQUID and GAMMAGARD S/D over placebo on measures of cognitive function and global impression of change, which are common measures of outcome in Alzheimer's disease clinical trials. The study also met secondary endpoints that measured changes in beta-amyloid and anti-amyloid antibody levels in blood and cerebrospinal fluid. Results show findings indicative of potential efficacy and tolerability. Key findings throughout six months included: measurements of clinical outcome, behavioral outcome and cognitive performance in Alzheimer's patients treated with GAMMAGARD S/D and GAMMAGARD LIQUID compared to placebo. Twelve-to-18 month data will be available later this year.

Secondary endpoint results suggest that levels of antibodies against beta-amyloid were observed to have increased in the blood and cerebrospinal fluid of patients treated with GAMMAGARD S/D and GAMMAGARD LIQUID, while the levels of beta-amyloid increased in the blood. Beta-amyloid is a substance thought to contribute to the degeneration of the brain in Alzheimer's disease. Clearing this substance from the central nervous system, therefore is hypothesized to help remove or reduce the building blocks of Alzheimer's.

The primary and secondary endpoint data were reported by the lead researcher for the trial, Dr. Norman Relkin, director of the Memory
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 , La ... contribuye a adquirir tolerancia a la proteína de ... proteína de la leche de la vaca (APLV) es la ... Hasta ahora, la APLV se trataba eliminando las ... demostrado que es posible adquirir tolerancia oral en ...
(Date:10/30/2014)... SAN FRANCISCO , Oct. 30, 2014 /PRNewswire/ ... rehydration solution (ORS), announced that it was awarded ... the leading healthcare services company that serves the ... Inc., UHC, Children,s Hospital Association and Provista.  ... designation based on feedback from member hospitals who ...
(Date:10/30/2014)... , Oct. 29, 2014 nebulizer is ... disorders (asthma, COPD and cystic fibrosis) that converts liquid ... easily reach into the lungs of a patient when ... global nebulizers market is dominated by various devices powered ... increasing prevalence of asthma, COPD and cystic fibrosis and ...
Breaking Medicine Technology:Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3
... 2010 Palatin Technologies, Inc. (NYSE Amex: PTN ... (the "Exchange"), advising Palatin that it is not in compliance ... Section 1003 of the Exchange,s Company Guide. In ... not in compliance with Section 1003(a)(iii) of the Company Guide ...
... 2, 2010 The Harley Medical Group is reporting a ... as an early present for themselves, the month before Christmas. ... to ensure a full recovery is made before they return ... procedures for Christmas 2010 include: Breast enlargement , Nose ...
Cached Medicine Technology:Palatin Technologies Receives Non-Compliance Letter from NYSE Amex 2Palatin Technologies Receives Non-Compliance Letter from NYSE Amex 3The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas 2
(Date:10/30/2014)... October 30, 2014 Five months after ... Hodgkinson Street LLC announces new branding and a website ... Mepham . After David Mepham’s promotion to name partner ... and website to include Mepham’s name and better reflect ... and mediation firm, the decision to implement new branding ...
(Date:10/30/2014)... Haelle HealthDay Reporter , ... 100 genes have been identified that appear linked to ... researchers say they are on their way to discovering ... the disorder. Autism spectrum disorders include a range ... and repetitive behaviors. An estimated one in 68 U.S. ...
(Date:10/30/2014)... Global prebiotics market is expected to reach ... study by Grand View Research, Inc. Positive outlook on ... fat free products owing to increased concerns over obesity ... the forecast period. , View full report with TOC ... was the largest application segment with market volume of ...
(Date:10/30/2014)... The Woodlands, TX (PRWEB) October 30, 2014 ... hospital system, released today its 2014 third quarter ... hospitals across Texas boasted infection rates of only ... also reported patient satisfaction scores exceeding 98 percent. ... this past quarter, which included rising satisfaction scores,” ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... lots of milk could be bad for your health, a ... calcium in milk can help strengthen bones and prevent osteoporosis. ... to recommend milk as part of a healthy diet. ... milk did not protect men or women from bone fractures, ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3
... , PITTSBURGH, July 27 Childhood obesity ... adults and can lead to premature death in adulthood due ... In addition to its significant human toll, childhood obesity alone ... , , To address the continued tide ...
... survey of men who opt out of aggressive treatment ... delay treatment for their early prostate cancer are not ... research shows. , The evidence seems to contradict the ... for most patients, according to Dr. Roderick van den ...
... YORK, July 27 Paradigm Spine, LLC, a developer of ... a $21.5 million financing, consisting of a $15mm debt facility ... lender in the $15mm venture debt funding. The $6.5 ... asset management group specializing in high-growth opportunities, and Trevi Health ...
... ... upcoming Materials and Processes for Medical Devices Conference , Aug. 10-12 at the Hilton ... (Vocus) July 27, ... upcoming Materials and Processes for Medical Devices Conference , Aug. 10-12 at the Hilton ...
... , , , ... tell people,s personalities based on the types of drink they enjoy. ... as sweet and indulgent, while someone who likes fruity drinks could be ... Angeles-based BLD & Grace Restaurants says the same could be said for ...
... Spanish . Capsule endoscopy for exploring ... all lesions located by means of conventional colonoscopy. According to ... Medicine the specialised medical journal with greatest international ... achieve similar efficacy to the conventional procedure undertaken with a ...
Cached Medicine News:Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 2Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 3Health News:Most Not Worried by Delayed Prostate Cancer Therapy 2Health News:Paradigm Spine Closes $21.5 Million Financing and Announces Promotion of Matt Stuttle to Position of Vice President, US Sales 2Health News:Paradigm Spine Closes $21.5 Million Financing and Announces Promotion of Matt Stuttle to Position of Vice President, US Sales 3Health News:Minnesotans to Keynote Materials for Medical Devices Conference 2Health News:Personality in a Cup 2Health News:Personality in a Cup 3Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 2Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 3Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 4Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: